Moderna has found a replacement for ousted CFO Jorge Gomez, announcing Wednesday that PerkinElmer executive James Mock will be its next finance chief.
The appointment of Mock comes several months after Moderna hired and then quickly fired Gomez from the role after it became known Gomez’ former employer, dental equipment manufacturer Dentsply Sirona, was investigating “certain financial reporting matters.”
Mock has served as CFO at PerkinElmer, a large life sciences and diagnostics firm, since 2018, overseeing several small acquisitions as well as a roughly $5.3 billion takeover of antibody and reagent provider BioLegend last year. On Aug. 1, PerkinElmer announced plans to divest its food and enterprise services division to a private equity firm for almost $2.5 billion.
Prior to PerkinElmer, Mock worked for nearly two decades at General Electric. READ MORE
By Ned Pagliarulo
Source: biopharmadive.com
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
